The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00559585




Registration number
NCT00559585
Ethics application status
Date submitted
15/11/2007
Date registered
16/11/2007
Date last updated
9/11/2015

Titles & IDs
Public title
Methotrexate-Inadequate Response Study
Scientific title
A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Secondary ID [1] 0 0
EUDRACT # 2007-005434-37
Secondary ID [2] 0 0
IM101-174
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis (RA) 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Subcutaneous (SC) Abatacept
Treatment: Drugs - Intravenous (IV) Abatacept

Active Comparator: Subcutaneous (SC) Abatacept - Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.

Active Comparator: Intravenous (IV) Abatacept - Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).


Treatment: Drugs: Subcutaneous (SC) Abatacept
Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.

Treatment: Drugs: Intravenous (IV) Abatacept
Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
500mg (for body weight up to 60 kg)
750 mg (body weight between 61 and 100 kg)
1g (body weight above 100 kg)infusions

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169 - The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Timepoint [1] 0 0
Day 169
Primary outcome [2] 0 0
Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population - Serum samples from all treated adult participants with active rheumatoid arthritis who were from the Anti-TNF failure population were screened for the presence of drug-specific antibodies using Enzyme Linked Immunoabsorbant Assay (ELISA). The number of participants who had the presence of anti-abatacept antibodies or anti-CTLA-4 antibodies present in their serum are summarized.
Timepoint [2] 0 0
Days 85, and 169 and postvisits on Days 28, 56, and 85
Secondary outcome [1] 0 0
Double-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169 - The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
Timepoint [1] 0 0
Day 169
Secondary outcome [2] 0 0
Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169 - The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered.
Timepoint [2] 0 0
Day 169
Secondary outcome [3] 0 0
Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI - The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0.
Timepoint [3] 0 0
Baseline to Day 169
Secondary outcome [4] 0 0
Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169 - The disability section of the full HAQ-DI includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3=unable to do. Higher scores=greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.
Timepoint [4] 0 0
Day 169
Secondary outcome [5] 0 0
Double-blind Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation - AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
Timepoint [5] 0 0
Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Secondary outcome [6] 0 0
Anti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs, AEs Leading to Discontinuation or Who Died - AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Timepoint [6] 0 0
Day 1 to 56 days after last dose in short-term or first dose in the long-term, whichever occurs first.
Secondary outcome [7] 0 0
Double-blind Period: Number of Participants With AEs of Special Interest - AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections,serious infections,and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (prespecified AEs occurring within 1 hr of start of infusion), peri-infusional AEs (prespecified AEs occurring within 24 hrs of the start of infusion), system injection reactions, and local injection site reactions
Timepoint [7] 0 0
Day 1 up to 56 days post last dose in short- term period or first dose in the long -term period, whichever occurs first.
Secondary outcome [8] 0 0
Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements - Vital sign measurements were performed for participants before and after infusion/subcutaneous injection of study medication at each visit and included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
Timepoint [8] 0 0
Day 1 through end of short-term period (Day 169)
Secondary outcome [9] 0 0
Double-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality - ULN=upper limit of normal; LLN=lower limit of normal; BL= baseline. Marked abnormality criteria: Hemoglobin: >3 g/dL decrease from BL; hematocrit: <0.75*BL; erythrocytes: <0.75*BL; platelets: <0.67*LLN/>1.5*ULN, or if BL<LLN, use <0.5*BL and <100,000 mm^3; leukocytes: <0.75*LLN/>1.25*ULN, or if BL<LLN use <0.8*BL or >ULN, or if BL>ULN, use >1.2*BL or <LLN; neutrophils+bands: <1.0*10^3 c/uL; eosinophils: >0.750*10^3 c/uL; basophils: >400 mm^3; monocytes: >2000 mm^3; lymphocytes: <0.750*10^3 c/uL/>7.50*10^3 c/uL.
Timepoint [9] 0 0
Day 1 through end of short-term period (Day 169)
Secondary outcome [10] 0 0
Double-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality - Marked abnormality criteria: Alkaline phosphatase (ALP): >2*ULN, or if BL>ULN, use >3*BL; aspartate aminotransferase (AST): >3*ULN, or if BL>ULN, use >4*BL; alanine aminotransferase (ALT): >3*ULN, or if BL>ULN, use >4*BL; G-glutamyl transferase (GGT): >2* ULN, or if BL>ULN, use >3*BL; bilirubin: >2* ULN, or if BL>ULN, use >4*BL; blood urea nitrogen: >2* BL; creatinine: >1.5*BL
Timepoint [10] 0 0
Day 1 through end of short-term period (Day 169)
Secondary outcome [11] 0 0
Double-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality - Marked abnormality criteria: Sodium: <0.95*LLN/>1.05*ULN, or if BL<LLN, use <0.95* BL or >ULN, or if BL>ULN, use>1.05* BL or <LLN; potassium: <0.9* LLN/>1.1*ULN, or if BL<LLN then use <0.9* BL or >ULN, or if BL>ULN, use>1.1* BL or <LLN; chlorine: <0.9*LLN/>1.1* ULN, or if BL<LLN, use <0.9*BL or >ULN, or if BL>ULN, use>1.1*BL or <LLN; calcium: <0.8* LLN/>1.2* ULN, or if BL<LLN, use <0.75*BL or >ULN, or if BL>ULN, use>1.25* BL or <LLN; phosphorous: <0.75* LLN/>1.25*ULN, or if BL<LLN, use 0.67*BL or >ULN, or if BL>ULN, use>1.33* BL or <LLN
Timepoint [11] 0 0
Day 1 through end of short-term period (Day 169)
Secondary outcome [12] 0 0
Double-blind Period: Minimum Observed Serum Concentration of Abatacept
Timepoint [12] 0 0
Days 57, 85, 113, 120, 127, 134, 141, and 169
Secondary outcome [13] 0 0
Anti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept - Serum concentrations of abatacept were analyzed using a validated ELISA. Steady-state trough observed concentration in serum (Cminss) was measured in µg/mL. Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169.
Timepoint [13] 0 0
Days 57, 85, 113, 120, 127, 134, 141, and 169 (ST Period)
Secondary outcome [14] 0 0
Double-blind Period: Maximum Observed Serum Concentration of Abatacept
Timepoint [14] 0 0
End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Secondary outcome [15] 0 0
Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept - Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Samples were obtained on Days 57, 85, 113, 120, 127, 134, 141, and 169. Cmax was measured in micrograms per milliliter (µg/mL).
Timepoint [15] 0 0
End of infusion on Days 1 and 113 for IV infusion and in the dosing interval of Days 113 to 120 for subcutaneous
Secondary outcome [16] 0 0
Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept
Timepoint [16] 0 0
Dosing interval between Days 113 and 141 (TAU=28 days)
Secondary outcome [17] 0 0
Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept - Serum concentrations of abatacept were analyzed using a validated ELISA. AUC(TAU) was measured as µg*h/mL. Samples for AUC (TAU) were obtained on Days 113, 120, 127, 134, and 141.
Timepoint [17] 0 0
Dosing Interval between Days 113 and 141 (TAU=28 days)
Secondary outcome [18] 0 0
Double-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA) - Serum samples from all treated adult participants with active rheumatoid arthritis were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept (anti-ABA) or anti-CTLA4 antibody (anti-CTLA4).
Timepoint [18] 0 0
Days 85, and 169 and postvisits on Days 28, 56, and 85
Secondary outcome [19] 0 0
Double-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period - C-reactive protein is an acute phase reactant protein that is a clinical marker for rheumatoid arthritis. Time-matched median percent change from baseline= (time-matched baseline value - Post-baseline value)/time-matched baseline value*100, where the time-matched baseline value represents the median baseline value for only that cohort of participants with measurements available at that visit.
Timepoint [19] 0 0
Baseline to Days 15, 29, 57, 85, 113, 141, and 169
Secondary outcome [20] 0 0
Double-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized - An electrochemiluminescence immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; abatacept molecule). Ig and/or Junction (JNCT) category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a postbaseline titer higher than Baseline, or any postbaseline positivity if Baseline value was missing. Trt=treatment.
Timepoint [20] 0 0
Days 85, and 169 and postvisits on Days 28, 56, and 85
Secondary outcome [21] 0 0
Double-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline - Rheumatoid factor (RF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process.
Timepoint [21] 0 0
Baseline to Day 169
Secondary outcome [22] 0 0
Open-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169, 729, 1261, and 1821 - The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).
Timepoint [22] 0 0
Days 169, 729, 1261, 1821
Secondary outcome [23] 0 0
Open-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169, 729, 1261, 1821 - The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein). ACR 70 is defined similarly with 70% improvements from baseline for tender and swollen joint counts and 3 out of 5 core measures.
Timepoint [23] 0 0
Days 169, 729, 1261, 1821
Secondary outcome [24] 0 0
Open-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169, 729, 1261, 1821 - The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6. A clinically significant response= decrease in DAS28 score of >1.2 from baseline.
Timepoint [24] 0 0
Days 169, 729, 1261, 1821
Secondary outcome [25] 0 0
Open-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169, 729, 1261, 1821 - The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6.
Timepoint [25] 0 0
Days 169, 729, 1261, 1821
Secondary outcome [26] 0 0
Open-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169, 729, 1261, 1821 - The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is > 5.1, low disease activity is < 3.2 and remission is < 2.6.
Timepoint [26] 0 0
Days 169, 729, 1261, 1821
Secondary outcome [27] 0 0
Open-Label LT Period: Number of Participants With HAQ-DI Response at Days 169, 729, 1261, 1821 - The disability section of the full HAQ includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. HAQ-DI overall score ranges from a minimum of 0 to a maximum of 3.0. HAQ response was defined as an improvement (reduction) from baseline (Day 1) of at least 0.3 units in the HAQ score.
Timepoint [27] 0 0
Days 169, 729, 1261, 1821
Secondary outcome [28] 0 0
Open-Label LT Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, or AEs Leading to Discontinuation - AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug
Timepoint [28] 0 0
End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Secondary outcome [29] 0 0
Open-Label LT Period: Number of Participants With AEs of Special Interest - AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs: all infections, serious infections, and opportunistic infections; autoimmune disorders; malignancies; system injection reactions, and local injection site reactions.
Timepoint [29] 0 0
End of ST Period (Day 169) to last dose plus 85 days, up to 5 years (September 2014)
Secondary outcome [30] 0 0
Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements - Vital sign assessments were performed in the LT period at 12-week intervals and at a yearly visit (at 16-week intervals) and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Vital signs included seated systolic blood pressure, seated diastolic blood pressure, temperature, and heart rate. Abnormalities were determined to be clinically significant by the investigator.
Timepoint [30] 0 0
End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)
Secondary outcome [31] 0 0
Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities - Laboratory assessments were performed in the LT period at 12-week intervals and at a yearly visit and, for participants who withdrew from the study prematurely, 7 days after the last dose of SC abatacept. Abnormalities were determined to be clinically significant by the investigator.
Timepoint [31] 0 0
End of ST Period (Day 169) to last dose plus 7 days, up to 5 years (September 2014)

Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com



- Subjects who are considered methotrexate inadequate responders

- 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint
count)
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies

- Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus
erythematous)

- Subjects with active vasculitis of a major organ system (except for subcutaneous
rheumatoid nodules)

- Subjects with severe chronic or recurrent bacterial infections

- Subjects who have received treatment with rituximab

An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using
the same treatment as the Main study in order to assess the immunogenicity and safety in
the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and
participants were permitted to roll into the LT Open Label Period.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - St Leonards
Recruitment hospital [2] 0 0
Local Institution - Cairns
Recruitment hospital [3] 0 0
Local Institution - Maroochydore
Recruitment hospital [4] 0 0
Local Institution - Woodville
Recruitment hospital [5] 0 0
Local Institution - Heidelberg
Recruitment hospital [6] 0 0
Local Institution - Shenton Park
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
QLD 4870 - Cairns
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
3081 - Heidelberg
Recruitment postcode(s) [6] 0 0
6008 - Shenton Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oklahoma
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
Rhode Island
Country [26] 0 0
United States of America
State/province [26] 0 0
South Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Virginia
Country [30] 0 0
United States of America
State/province [30] 0 0
Washington
Country [31] 0 0
Argentina
State/province [31] 0 0
Buenos Aires
Country [32] 0 0
Argentina
State/province [32] 0 0
Santa Fe
Country [33] 0 0
Argentina
State/province [33] 0 0
Cordoba
Country [34] 0 0
Argentina
State/province [34] 0 0
Tucuman
Country [35] 0 0
Belgium
State/province [35] 0 0
Bruxelles
Country [36] 0 0
Belgium
State/province [36] 0 0
Hasselt
Country [37] 0 0
Belgium
State/province [37] 0 0
Leuven
Country [38] 0 0
Belgium
State/province [38] 0 0
Wilrijk
Country [39] 0 0
Belgium
State/province [39] 0 0
Yvoir
Country [40] 0 0
Brazil
State/province [40] 0 0
Goias
Country [41] 0 0
Brazil
State/province [41] 0 0
Minas Gerais
Country [42] 0 0
Brazil
State/province [42] 0 0
Parana
Country [43] 0 0
Brazil
State/province [43] 0 0
Pernambuco
Country [44] 0 0
Brazil
State/province [44] 0 0
Rio Grande Do Sul
Country [45] 0 0
Brazil
State/province [45] 0 0
Sao Paulo
Country [46] 0 0
Brazil
State/province [46] 0 0
Rio De Janeiro
Country [47] 0 0
Canada
State/province [47] 0 0
Manitoba
Country [48] 0 0
Canada
State/province [48] 0 0
Newfoundland and Labrador
Country [49] 0 0
Canada
State/province [49] 0 0
Ontario
Country [50] 0 0
Canada
State/province [50] 0 0
Quebec
Country [51] 0 0
Canada
State/province [51] 0 0
Saskatchewan
Country [52] 0 0
Chile
State/province [52] 0 0
Metropolitana
Country [53] 0 0
France
State/province [53] 0 0
Bordeaux Cedex
Country [54] 0 0
France
State/province [54] 0 0
Brest Cedex
Country [55] 0 0
France
State/province [55] 0 0
Chambray Les Tours
Country [56] 0 0
France
State/province [56] 0 0
Le Mans
Country [57] 0 0
France
State/province [57] 0 0
Lille Cedex
Country [58] 0 0
France
State/province [58] 0 0
Marseille
Country [59] 0 0
France
State/province [59] 0 0
Nice Cedex 3
Country [60] 0 0
France
State/province [60] 0 0
Paris Cedex 13
Country [61] 0 0
France
State/province [61] 0 0
Paris Cedex 14
Country [62] 0 0
France
State/province [62] 0 0
Poitiers
Country [63] 0 0
France
State/province [63] 0 0
Strasbourg Cedex
Country [64] 0 0
Germany
State/province [64] 0 0
Berlin
Country [65] 0 0
Germany
State/province [65] 0 0
Leipzig
Country [66] 0 0
Germany
State/province [66] 0 0
Muenchen
Country [67] 0 0
Germany
State/province [67] 0 0
Munchen
Country [68] 0 0
Greece
State/province [68] 0 0
Heraklion Crete
Country [69] 0 0
Hungary
State/province [69] 0 0
Budapest
Country [70] 0 0
Hungary
State/province [70] 0 0
Debrecen
Country [71] 0 0
India
State/province [71] 0 0
Andhra Pradesh
Country [72] 0 0
India
State/province [72] 0 0
Gujarat
Country [73] 0 0
India
State/province [73] 0 0
Karnataka
Country [74] 0 0
India
State/province [74] 0 0
Bangalore
Country [75] 0 0
India
State/province [75] 0 0
Hyderabad
Country [76] 0 0
India
State/province [76] 0 0
Lucknow
Country [77] 0 0
India
State/province [77] 0 0
New Delhi
Country [78] 0 0
Ireland
State/province [78] 0 0
Dublin
Country [79] 0 0
Italy
State/province [79] 0 0
Napoli
Country [80] 0 0
Italy
State/province [80] 0 0
Padova
Country [81] 0 0
Italy
State/province [81] 0 0
Pavia
Country [82] 0 0
Italy
State/province [82] 0 0
Roma
Country [83] 0 0
Italy
State/province [83] 0 0
Siena
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Sungdong-Gu
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Daegu
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Daejeon
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Seoul
Country [88] 0 0
Mexico
State/province [88] 0 0
Baja California
Country [89] 0 0
Mexico
State/province [89] 0 0
Distrito Federal
Country [90] 0 0
Mexico
State/province [90] 0 0
Jalisco
Country [91] 0 0
Mexico
State/province [91] 0 0
Michioacan
Country [92] 0 0
Mexico
State/province [92] 0 0
Yucatan
Country [93] 0 0
Mexico
State/province [93] 0 0
Aguascalientes
Country [94] 0 0
Mexico
State/province [94] 0 0
Chihuahua
Country [95] 0 0
Mexico
State/province [95] 0 0
Nuevo Leon
Country [96] 0 0
Mexico
State/province [96] 0 0
Queretaro
Country [97] 0 0
Mexico
State/province [97] 0 0
San Luis Potosi
Country [98] 0 0
Netherlands
State/province [98] 0 0
Leeuwarden
Country [99] 0 0
Peru
State/province [99] 0 0
Callao
Country [100] 0 0
Peru
State/province [100] 0 0
Lima
Country [101] 0 0
Poland
State/province [101] 0 0
Bialystok
Country [102] 0 0
Poland
State/province [102] 0 0
Bydgoszcz
Country [103] 0 0
Poland
State/province [103] 0 0
Konskie
Country [104] 0 0
Poland
State/province [104] 0 0
Krakow
Country [105] 0 0
Poland
State/province [105] 0 0
Poznan
Country [106] 0 0
Poland
State/province [106] 0 0
Torun
Country [107] 0 0
Poland
State/province [107] 0 0
Warszawa
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Ekaterinburg
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Moscow
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Yaroslavl
Country [111] 0 0
South Africa
State/province [111] 0 0
Gauteng
Country [112] 0 0
South Africa
State/province [112] 0 0
Kwa Zulu Natal
Country [113] 0 0
South Africa
State/province [113] 0 0
Western Cape
Country [114] 0 0
Taiwan
State/province [114] 0 0
Kaohsiung
Country [115] 0 0
Taiwan
State/province [115] 0 0
Taichung
Country [116] 0 0
Turkey
State/province [116] 0 0
Denizli
Country [117] 0 0
Turkey
State/province [117] 0 0
Edirne
Country [118] 0 0
Turkey
State/province [118] 0 0
Gaziantep
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Cambridgeshire
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Glamorgan
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Greater London
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Hampshire
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Tyne And Wear

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept
yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in
participants with rheumatoid arthritis and an inadequate response to current methotrexate
therapy.
Trial website
https://clinicaltrials.gov/show/NCT00559585
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications